References
- Swiss Association for the Study of the Liver. Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir. Swiss Med Wkly 2012;142:w13516.
- Karino T, Ozeki I, Hige S, Kimura M, Arakawa T, Nakajima T, et al. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. J Viral Hepat 2014;21:341–7.
- Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433–44.
- Kunze A, Huwyler J, Camenisch G, Gutmann H. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol 2012;84:1096–102.
- Fukuda K, Imai Y, Hiramatsu N, Irishio K, Igura T, Sawai Y, et al. Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C. Hepatol Res 2014;44:1165–71.
- Schneider MP, Genre N, Reymermier M, Bugnon O, Moradpour D. Hepatits C, Therapeutische Fortschritte. Pharma Journal 2012;25:9–13.
- Mauss S, Hueppe D, Alshuth U. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology 2014;59:46–8.
- Loustaud-Ratti V, Carrier P, Vong C, Essig M. Reply to: Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology 2014;59:2426.
- Loustaud-Ratti V, Rousseau A, Carrier P, Vong C, Chambaraud T, Jacques J, et al. eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance? Liver Int 2015;35:71–8.
- Remy AJ, Lesgourgues B, Nalet B, Causse X, Henrion J, Denis J, et al. Renal dysfunction associated with telaprevir-containing triple therapy for chronic hepatitis C: is early prediction possible? Eur J Gastroenterol Hepatol 2014;26:996–1002.
- Kikuchi H, Numao H. Telaprevir-induced acute kidney injury during treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol 2014;26:244–5.
- Veiga Z, Pereira GH, Fernandes FF, Mariz DM, Pereira JL. Reply to: Telaprevir-induced acute kidney injury during treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol 2014;26:687–8.
- Carrier P, Chambaraud T, Vong C, Guillaudeau A, Debette-Gratien M, Jacques J, et al. Severe renal impairment during triple therapy with telaprevir. Clin Res Hepatol Gastroenterol 2014;38:e69–71.
- Virlogeux V, Pradat P, Bailly F, Funingana G, Gonçalves F, Maynard M, et al. Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score. J Viral Hepat 2014;21:e98–e107.
- Incivo®. Available from: www.swissmedicinfo.ch [accessed 31 January 2014].
- Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013;381:735–43.
- Dumortier J, Guillaud O, Gagnieu MC, Janbon B, Juillard L, Morelon E, et al. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? J Clin Virol 2013;56:146–9.